NEOG
Neogen Corporation NASDAQ Listed Aug 23, 1989$9.31
+4.26%
vs $8.93
Mkt Cap $2.0B
52w Low $4.56
69.1% of range
52w High $11.43
50d MA $9.13
200d MA $8.10
P/E (TTM)
-1.9x
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.4x
ROE
-52.2%
P/FCF
-43.6x
RSI (14)
56.80
ATR (14)
$0.32
Beta
1.97
50d MA
$9.13
200d MA
$8.10
Avg Volume
2.5M
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
620 Lesher Place · Lansing, MI 48912 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9, 2026 | AMC | 0.04 | 0.09 | +125.0% | 10.04 | -0.8% | -6.2% | -3.0% | +5.1% | -2.0% | -1.9% | — |
| Jan 8, 2026 | AMC | 0.07 | 0.10 | +42.9% | 9.71 | +2.8% | -0.9% | -2.6% | -1.9% | +2.2% | +0.7% | — |
| Oct 9, 2025 | AMC | -0.07 | 0.04 | +154.1% | 6.78 | +1.5% | -10.9% | -1.5% | -0.7% | +0.7% | -0.3% | — |
| Jul 29, 2025 | AMC | 0.08 | 0.05 | -37.5% | 4.83 | -0.4% | -2.7% | -1.1% | +0.2% | +0.4% | +0.0% | — |
| Apr 9, 2025 | AMC | 0.13 | 0.10 | -23.1% | 5.02 | +2.4% | +12.2% | -0.9% | -3.2% | -8.3% | -7.1% | — |
| Jan 10, 2025 | AMC | 0.09 | 0.11 | +22.2% | 12.36 | -0.6% | +2.3% | -5.1% | -5.3% | +2.1% | -0.3% | — |
| Oct 10, 2024 | AMC | 0.09 | 0.07 | -17.6% | 13.79 | +0.1% | +4.6% | -2.8% | +5.1% | -0.8% | -1.0% | — |
| Jul 30, 2024 | AMC | 0.12 | 0.10 | -16.7% | 17.58 | -0.5% | -3.1% | -0.2% | -3.6% | -1.4% | +3.7% | — |
| Apr 9, 2024 | AMC | 0.14 | 0.12 | -14.3% | 13.04 | -1.7% | -4.1% | +4.0% | -4.8% | -3.0% | +1.2% | — |
| Jan 9, 2024 | AMC | 0.15 | 0.11 | -26.7% | 18.18 | -0.4% | +3.1% | -3.1% | +0.1% | -1.0% | -6.2% | — |
| Oct 10, 2023 | AMC | 0.14 | 0.11 | -21.4% | 16.06 | -0.4% | -6.8% | +0.0% | +3.3% | -0.5% | -1.6% | — |
| Jul 27, 2023 | AMC | 0.10 | 0.14 | +40.0% | 22.25 | +1.3% | +3.8% | +0.4% | -2.6% | +0.1% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $9.62 | $9.62 | +0.0% | -2.6% | -1.9% | +2.2% | +0.7% | -2.2% |
| Jan 9 | Guggenheim | Maintains | Buy → Buy | — | $9.71 | $9.98 | +2.8% | -0.9% | -2.6% | -1.9% | +2.2% | +0.7% |
| Dec 10 | CJS Securities | Upgrade | Market Perform → Market Outperform | — | $6.40 | $6.39 | -0.2% | +9.1% | +0.9% | -2.6% | -0.1% | +2.8% |
| Oct 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.95 | $6.08 | +2.2% | -0.3% | -0.8% | +0.2% | +0.2% | +4.1% |
| Jul 29 | William Blair | Downgrade | Outperform → Market Perform | — | $5.42 | $4.96 | -8.5% | -10.9% | -2.7% | -1.1% | +0.2% | +0.4% |
| Jun 30 | Guggenheim | Maintains | Buy → Buy | — | $4.73 | $4.69 | -0.8% | +1.1% | +6.3% | +3.0% | +1.9% | -6.6% |
| Apr 22 | Piper Sandler | Maintains | Neutral → Neutral | — | $4.69 | $4.65 | -0.9% | +1.3% | +3.6% | +5.7% | -0.8% | -0.4% |
| Apr 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.58 | $5.68 | +1.8% | -3.2% | -8.3% | -7.1% | -4.6% | +6.8% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $5.02 | $5.14 | +2.4% | +12.2% | -0.9% | -3.2% | -8.3% | -7.1% |
| Jan 21 | Piper Sandler | Maintains | Neutral → Neutral | — | $11.56 | $11.47 | -0.8% | +1.6% | +1.8% | -1.8% | -2.3% | +3.1% |
| Aug 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.15 | $16.11 | -0.2% | +3.7% | -2.2% | +3.7% | -1.1% | -2.3% |
| Apr 15 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.38 | $12.26 | -1.0% | -3.0% | +1.2% | -0.2% | -1.7% | -2.7% |
| Jan 18 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.88 | $17.02 | +0.8% | +0.7% | +0.1% | -1.2% | -0.1% | -2.5% |
| Oct 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.47 | $15.45 | -0.1% | -0.5% | -1.6% | +1.3% | -2.3% | +0.4% |
| Aug 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $22.50 | $22.75 | +1.1% | +4.9% | +1.0% | -3.2% | -2.3% | -0.2% |
| Dec 15 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.35 | $15.16 | -1.2% | -1.4% | -1.7% | -1.6% | -0.5% | +2.5% |
| Nov 22 | William Blair | Upgrade | Market Perform → Outperform | — | $15.45 | $16.01 | +3.6% | +2.8% | +2.0% | +0.4% | -6.3% | +1.6% |
| Oct 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.68 | $12.75 | +0.6% | -4.5% | -3.6% | +4.5% | -0.5% | -6.7% |
| Aug 30 | Piper Sandler | Maintains | Neutral → Neutral | — | $21.54 | $21.24 | -1.4% | -1.7% | -1.3% | -9.1% | -5.1% | -6.0% |
| Aug 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $23.13 | $23.08 | -0.2% | -2.4% | -2.1% | +0.3% | -2.8% | -0.6% |
| Jul 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $22.88 | $22.74 | -0.6% | -1.0% | -3.5% | -1.1% | +4.1% | -3.6% |
| Mar 19 | Craig-Hallum | Upgrade | Hold → Buy | — | $31.53 | $32.22 | +2.2% | +1.5% | -0.1% | +0.1% | -6.7% | +1.4% |
| Mar 27 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $33.08 | $33.01 | -0.2% | -0.8% | +1.6% | +0.5% | -2.2% | +2.1% |
| Jul 14 | CL King | Maintains | Neutral → Neutral | — | $25.53 | $25.43 | -0.4% | +0.3% | +0.2% | -5.5% | +3.5% | +1.0% |
| Dec 22 | Craig-Hallum | Downgrade | Buy → Hold | — | $22.60 | $21.57 | -4.6% | -5.7% | +2.2% | +0.3% | -0.3% | +0.1% |
| Mar 17 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $19.12 | $18.76 | -1.9% | -3.3% | -0.9% | +2.1% | +0.9% | +0.8% |
| Aug 11 | TD Cowen | Maintains | Market Perform → Hold | — | $16.59 | $16.58 | -0.1% | +0.6% | +0.8% | +0.2% | +0.2% | -0.1% |
| Aug 15 | Janney Capital | Maintains | Neutral → Neutral | — | $14.25 | $14.03 | -1.5% | -1.2% | -3.0% | -0.7% | -1.0% | +0.7% |
| Jul 24 | Wellington Shields | Downgrade | Hold → Sell | — | $14.57 | $14.25 | -2.2% | -3.5% | +2.5% | -0.3% | -1.4% | -0.1% |
No insider trades available.
8-K · 7.01
! Medium
Neogen Corp -- 8-K 7.01: Regulation FD Disclosure
Neogen is advancing manufacturing validation of its Petrifilm product line ahead of facility tours, signaling progress toward increased production capacity and commercial expansion.
Apr 20
8-K
Unknown — 8-K Filing
NEOG's Food Safety segment momentum suggests a successful turnaround is underway, potentially justifying higher valuations if stabilization continues in coming quarters.
Apr 9
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive appointment to external board leadership suggests confidence in management quality and may signal stability, though investors should monitor whether divided attention impacts operational focus at the primary company.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide meaningful analysis because the filing excerpt contains only formatting code and incomplete header information without disclosing which executive changed roles or their significance to NEOG's operations and strategy.
Mar 30
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 12,832,264 | $119M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 9,565,046 | $89M | New | Mar 2026 |
| 3 | Neuberger Berman Group Llc | 7,751,718 | $72M | Added | Mar 2026 |
| 4 | Morgan Stanley | 8,992,662 | $63M | Reduced | Dec 2025 |
| 5 | Sg Americas Securities, Llc | 6,266,033 | $58M | Added | Mar 2026 |
| 6 | Cibc Bancorp Usa Inc. | 5,993,222 | $56M | Added | Mar 2026 |
| 7 | Cibc World Market Inc. | 5,961,600 | $55M | New | Mar 2026 |
| 8 | Hudson Bay Capital Management Lp | 6,500,000 | $45M | Added | Dec 2025 |
| 9 | Bank Of America Corp /de/ | 4,640,534 | $43M | Added | Mar 2026 |
| 10 | Mizuho Markets Americas Llc | 3,500,000 | $33M | — | Mar 2026 |
| 11 | Healthcare Of Ontario Pension Plan Trust Fund | 3,297,346 | $31M | Reduced | Mar 2026 |
| 12 | Bnp Paribas Financial Markets | 2,517,129 | $23M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 2,361,279 | $22M | Added | Mar 2026 |
| 14 | Clarkston Capital Partners, Llc | 2,204,788 | $20M | Reduced | Mar 2026 |
| 15 | Nomura Holdings Inc | 2,088,042 | $19M | Added | Mar 2026 |
| 16 | Fmr Llc | 1,905,343 | $18M | Added | Mar 2026 |
| 17 | Glenmede Trust Co Na | 1,829,298 | $17M | New | Mar 2026 |
| 18 | Ubs Group Ag | 1,512,464 | $14M | Reduced | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 1,246,638 | $12M | Reduced | Mar 2026 |
| 20 | Nuveen, Llc | 1,207,784 | $11M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.03B
Enterprise Value
$2.77B
P/E (TTM)
-1.85x
Forward P/E
26.04x
PEG Ratio
-0.00x
P/B
0.97x
P/S
2.26x
P/FCF
-43.57x
EV/EBITDA
—
Shares Out
216.9M
Financials (TTM)
Revenue
$894.7M
Net Income
-$1.09B
EBITDA
-$937.8M
Free Cash Flow
-$46.4M
Op Cash Flow
$58.2M
EPS Basic
$-5.03
EPS Diluted
$-5.03
EPS Forward
$0.36
Gross Margin
47.1%
Op Margin
1.1%
Net Margin
-122.1%
Balance Sheet
Total Assets
$3.44B
Total Liab.
$1.37B
Total Equity
$2.07B
Cash
$129.0M
LT Debt
$874.8M
Book Value/Sh
$9.55
Debt/Equity
0.44x
Current Ratio
3.32
Quick Ratio
2.22
Returns & Growth
ROE
-52.2%
ROA
-32.7%
ROIC
0.3%
Rev Growth YoY
-3.2%
EPS Growth YoY
-11463.2%
Price Returns
2W
+6.4%
1M
-4.6%
3M
-20.1%
6M
+50.0%
12M
+53.1%
Technicals
52W High
$11.43
52W Low
$4.56
50d MA
$9.13
200d MA
$8.10
RSI (14)
56.80
ATR (14)
$0.32
Beta
1.97
Avg Volume
2.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$12.00
Low
$10.00
Median
$11.00
Data updated apr 26, 2026 2:40pm
· Source: financialmodelingprep.com